trans-1,4-Dibromo-2-butene CAS 821-06-7 Purity ≥99.0% (GC) Factory High Quality
Umenzi onoMgangatho oPhezulu kunye neXabiso loKhuphiswano
Ubonelelo ngezoRhwebo lwe-Aliskiren oluNxulumeneyo lwabaPhakathi:
Aliskiren CAS: 173334-57-1
Aliskiren Hemifumarate CAS: 173334-58-2
(S)-4-Benzyl-2-Oxazolidinone CAS: 90719-32-7
(R)-4-Benzyl-2-Oxazolidinone CAS: 102029-44-7
trans-1,4-Dibromo-2-Butene CAS: 821-06-7
Isovaleryl Chloride CAS: 108-12-3
D-Phenylalanine CAS: 673-06-3
I-D-Phenylalaninol CAS: 5267-64-1
| Igama leMchiza | trans-1,4-Dibromo-2-Butene |
| Izithethantonye | (E)-1,4-Dibromobut-2-ene;(2E)-1,4-Dibromo-2-butene |
| Inombolo yeCAS | 821-06-7 |
| Inombolo yeCAT | RF-PI149 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | C4H6Br2 |
| Ubunzima beMolekyuli | 213.9 |
| Ukunyibilika kwiMethanol | Phantse Ukungafihli |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Okumhlophe ukuya kuBrown Okuqinileyo |
| Ubunyulu / Indlela yokuHlalutya | ≥99.0% (GC) |
| Cis-Umxholo | ≤0.20% |
| Indawo yokunyibilika | 50.0℃~54.0℃ |
| I-Tetrabromobutane (TBB) | ≤0.50% |
| Ukufuma (KF) | ≤0.20% |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | Aliskiren (CAS 173334-57-1), Aliskiren Hemifumarate (CAS 173334-58-2) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi okhokelayo kunye nomthengisi we-trans-1,4-Dibromo-2-Butene (i-CAS: 821-06-7) enomgangatho ophezulu, esetyenziswa ngokubanzi kwi-organic synthesis, i-synthesis ye-pharmaceutical intermediates. isithako esisebenzayo seyeza (API) synthesis.
i-trans-1,4-Dibromo-2-Butene (i-CAS: 821-06-7) ingundoqo ephakathi kwi-synthesis ye-Aliskiren (CAS: 173334-57-1), i-API.I-Aliskiren iyiyeza lokuqala kwiklasi ye-antihypertensive eyenza ngokunqanda ngokuthe ngqo kwe-renin.Iboniswa kulawulo lomlomo mhlawumbi njenge-monotherapy okanye ngokudibanisa nezinye i-antihypertensive agents.Ukuvinjwa kwe-renin nge-aliskiren kubangela amanqanaba ancitshisiweyo e-angiotensin I, i-angiotensin II, kunye ne-aldosterone, zonke ezinegalelo kwimpembelelo ye-antihypertensive.
